Distinct immune-effector and metabolic profile of CD8 + T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors.
Karolina BenesovaFranziska Viktoria KrausRui A CarvalhoHolger LorenzChristian H HörthJanine GüntherKarel D KlikaJürgen GrafLeonore DiekmannTimo SchankPetros ChristopoulosJessica C HasselHanns-Martin LorenzM Margarida Souto-CarneiroPublished in: Annals of the rheumatic diseases (2022)
Our study shows that CD8 from ICI-treated patients who develop a musculoskeletal irAE has a distinct immune-effector and metabolic profile from those that remain irAE free. This specific irAE profile overlaps with the one observed in CD8 from AA patients and may prove useful for novel therapeutic strategies to manage ICI-induced irAEs.
Keyphrases
- newly diagnosed
- end stage renal disease
- ejection fraction
- regulatory t cells
- dendritic cells
- chronic kidney disease
- multiple sclerosis
- prognostic factors
- drug induced
- high glucose
- diabetic rats
- oxidative stress
- endothelial cells
- type iii
- immune response
- mesenchymal stem cells
- nk cells
- bone marrow
- patient reported outcomes